Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Complete responses were observed in a small cohort of patients with DLBCL who have previously received autologous CAR T-cell therapy.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Efficacy, safety, time, and cost were all factors assessed between subcutaneous and intravenous rituximab for patients with non-Hodgkin lymphoma.

Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.

Brentuximab vedotin plus chemotherapy significantly improved HRQOL in both pediatric and young adult patients with high-risk Hodgkin lymphoma.

The approval of epcoritamab may impact treatment options in the R/R follicular lymphoma space, according to Tycel Phillips, MD.